Tilray Pharma Signs £1B UK Distribution Pact to Expand Medical Cannabis Reach
Tilray Pharma has signed a strategic distribution agreement with Smartway Pharmaceuticals through CC Pharma to expand its medical cannabis and pharmaceutical products across the UK. The UK pharmaceutical market for these products is estimated at nearly £1 billion, aiming to improve supply reliability and strengthen Tilray’s European medical strategy.
1. UK Distribution Agreement
Tilray Pharma’s European arm CC Pharma has entered into a binding agreement with Smartway Pharmaceuticals, leveraging Smartway’s national UK network to distribute Tilray’s medicinal cannabis and related pharmaceutical products across pharmacies and hospitals.
2. Market Potential
The partnership targets a UK market estimated at nearly £1 billion for these medical products, presenting a significant revenue opportunity as Tilray seeks to deepen its footprint in one of Europe’s largest healthcare markets.
3. Strategic Benefits
The deal is designed to enhance supply reliability through Smartway’s established infrastructure, while embedding Tilray more deeply into the UK health system and supporting its long-term European medical strategy.